Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent ; A Systematic Review

Title: Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent ; A Systematic Review
Authors: Attard, Joseph A.; Farrugia, Alexia; Pathanki, Adithya; Roberts, Keith J.; Dasari, Bobby; Isaac, John; Ma, Yuk Ting; Chatzizacharias, Nikolaos A.
Source: Pancreas ; volume 49, issue 10, page 1264-1275 ; ISSN 1536-4828 0885-3177
Publisher Information: Ovid Technologies (Wolters Kluwer Health)
Publication Year: 2020
Description: Historically, locally advanced pancreatic adenocarcinoma (LAPDAC) was considered a palliative condition. Advances in treatment have resulted in studies reporting survival after neoadjuvant treatment and surgery similar to earlier disease stages. However, there is no consensus on optimal LAPDAC management. Our aim was a systematic review of published evidence on LAPDAC treatment strategies with curative intent. Twenty-eight studies defining LAPDAC as per established criteria and reporting outcomes after neoadjuvant treatment with a view to resection were included. Primary outcomes were resection rate and proportion of curative resections. Secondary outcomes were postoperative mortality, progression-free survival, and overall survival. Neoadjuvant treatment varied significantly, most common being the combination of folinic acid, fluorouracil, irontecan, and oxaliplatin. Median percentage of patients proceeding to surgery after completion of neoadjuvant pathway was 33.5%. Median resection rate was 25%. Median R0 resection was 80% of resected patients. These outcomes ranged 0% to 100% across studies. Ninety-day postoperative mortality ranged from 0% to 5%. Median progression-free and overall survival for resected patients were 12.9 and 30 months, respectively, versus 13.2 months overall survival for unresected patients. In conclusion, although there is wide variability in reported LAPDAC resection rates post–neoadjuvant chemotherapy, retrospective data suggest that neoadjuvant treatment followed by surgery results in improved survival.
Document Type: article in journal/newspaper
Language: English
DOI: 10.1097/mpa.0000000000001694
DOI: 10.1097/MPA.0000000000001694
Availability: https://doi.org/10.1097/mpa.0000000000001694; https://journals.lww.com/10.1097/MPA.0000000000001694
Accession Number: edsbas.F869D77
Database: BASE